Project Grant R01AG092782
- Federal Grant Award Summary The University of Florida Division of Sponsored Research received a $2.78 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective July 1, 2026, through June 30, 2030. This award supports research directed toward identifying early neural signatures of prodromal Alzheimer's disease (AD) that can distinguish between early cognitive decline and normal aging. The project delivers two primary research...
- Federal Grant Award Summary The University of Florida's Division of Sponsored Research received a $507,214 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with a completion date of January 31, 2028. This exploratory/developmental R21 grant supports systematic investigation of long-noncoding RNA SLAMR (SLAMR lncRNA) and its role in Alzheimer's disease pathogenesis. The research aims to elucidate how SLAMR...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of South Florida $3.297 million under the Aging Research program (CFDA 93.866) for a four-year project period (September 1, 2025 – August 31, 2029) to develop novel peptidomimetic biomaterials that inhibit amyloid-beta (Aβ42) aggregation in Alzheimer's disease. The research deliverables include the rational design and characterization of structurally related analogues to a lead compound that stabilizes Aβ...
- Federal Project Grant Award Summary The University of Florida's Division of Sponsored Research received a $126,640 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) effective September 1, 2025, through May 31, 2030. This research initiative applies machine learning approaches to develop a robust, standardized measure of allostatic load (AL)—a physiological indicator of cumulative "wear and tear" that serves as a pre-clinical marker for chronic...
- Federal Grant Award Summary The University of Florida Division of Sponsored Research received a $182,570 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective July 1, 2026, through April 30, 2031. This K23 career development award supports a prospective cohort study investigating Diffuse Optical Tomography (DOT) as a portable neuroimaging biomarker for mapping brain function changes associated with delirium and subsequent...
- Federal Grant Award Summary The National Institute on Aging awarded a $1.28 million Project Grant under the Aging Research program (CFDA 93.866) to the University of Arizona, effective August 1, 2025, through May 31, 2030. The award funds research investigating the relationship between liquid-liquid phase separation (LLPS) of transactive response DNA binding protein of 43 kDa (TDP-43) and mitochondrial dysfunction in neurodegeneration. TDP-43 mutations are associated with amyotrophic lateral...
- Federal Project Grant Award Summary The University of Florida's Division of Sponsored Research received a $2.33 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 1, 2025, through August 31, 2029. The award funds research evaluating neuroimmune mechanisms and therapeutic targeting potential of the luteinizing hormone/chorionic gonadotropin (LH/CG) receptor in menopausal and Alzheimer's disease-affected brains....
- Federal Project Grant Award Summary The National Institute on Aging awarded a Project Grant of $439,739 to the University of Florida Division of Sponsored Research, effective June 1, 2026 through May 31, 2028, under the Aging Research program (CFDA 93.866). This R01 award from an Early-Stage Investigator funds a longitudinal research study examining the biobehavioral signatures of repetitive head impacts (RHI) at the intersection of aging and Alzheimer's disease. The research will investigate...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded the University of Florida's Division of Sponsored Research $405,045 under the Aging Research program (CFDA 93.866) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This project grant funds research investigating the neurophysiology of locomotor adaptation and freezing of gait (FOG) in Parkinson's disease (PD). The research will deliver scientific knowledge regarding the neural...
- Federal Project Grant Summary The National Institute on Aging (NIA) awarded University of Massachusetts Medical School $3.32M through the Aging Research program (CFDA 93.866) on August 15, 2025, for a four-year research project concluding July 31, 2029. The award supports collaborative research by the Bosco and Massi laboratories investigating the molecular mechanisms underlying profilin-1 (PFN1)-mediated amyotrophic lateral sclerosis (ALS), a uniformly lethal neurodegenerative disease. The...
The University of Florida's Division of Sponsored Research received a $730,938 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective July 1, 2026 through May 31, 2031. The award funds research to develop and refine combinatorial rehabilitation treatments for individuals with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron loss, paralysis, and respiratory failure. Specifically, the project will develop and test therapeutic acute intermittent hypoxia (TAIH) protocols as a pre-treatment enhancement to conventional rehabilitation, with the objective of amplifying and prolonging functional benefits in respiratory and limb motor systems for ALS patients. The research deliverables include refinement of repetitive TAIH protocols in unaffected adult populations and the first clinical evaluation of repeated TAIH treatments in ALS patients. The project is grounded in decades of rodent model research demonstrating that TAIH elicits neuromotor plasticity through mechanisms involving spinal serotonin and adenosine regulation. Outcomes will contribute to expanding limited rehabilitation options currently available for ALS patients by providing evidence-based, combinatorial treatment approaches capable of improving mobility and independent breathing ability in this medically underserved population.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $730.9k | 6/30/26 |